Human Resources
A Voice for health equity: Organon and J&J leaders champion the Voice to Parliament as a catalyst for change

Human Resources: In a thought-provoking interview with Health Industry Hub, industry leaders from the pharma and medtech sectors shed light on the significance of the Voice to Parliament in closing the gap in health equity for Aboriginal and Torres Strait Islander peoples.
With the upcoming referendum on the Voice to Parliament, Meshlin Khouri, Associate Director of Policy and Communications at Organon and Deborah Guion, Head of Global Community Impact at Johnson & Jonson expressed their organisations’ commitment to educating and raising awareness among their employees about the referendum and its potential implications. They recognised the historic nature of this moment and acknowledged the Voice to Parliament as a critical step towards reconciliation and creating a more inclusive nation.
In addressing some of the misconceptions and myths surrounding the Voice to Parliament, Deb and Meshlin highlighted the importance of engaging in open and respectful dialogue with individuals who may hold different perspectives. They emphasised the need for active listening and understanding to address concerns and dispel myths surrounding the referendum.
Meshlin stressed the importance of addressing existing healthcare inequities, particularly for women, and how the Uluru statement from the Heart aligns with Organon’s commitment to inclusivity and addressing disparities.
Deb emphasised that as corporate citizens, Johnson & Johnson has a responsibility to equip their workforce with the necessary knowledge to make informed choices. Understanding the history, significance, and potential impact of the Voice, will contribute to a more equitable and inclusive healthcare system.
As the conversation drew to a close, both health leaders highlighted the significance of this moment in the nation’s history and the need for active participation and informed choices from all.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
Digital & Innovation
Health sector faces new privacy obligations
Healthcare organisations must update their privacy policies by 10 December if they use artificial intelligence (AI) or a computer program […]
MoreNews - Pharmaceuticals
TGA approves new antibiotic but AMR blind spot remains a critical concern
The Therapeutic Goods Administration (TGA) has approved a new antibiotic for the treatment of carbapenem-resistant Gram-negative bacterial infections. Developed by […]
MoreNews - MedTech & Diagnostics
BCAL Diagnostics rejects merger speculation
ASX-listed BCAL Diagnostics has moved to quash speculation of a potential three-way merger involving Genetic Signatures and Microba Life Sciences, […]
MoreNews - Pharmaceuticals
Australia backs infectious disease innovation as US funding faces more cuts
Biointelect Venturer, a national incubator supporting infectious disease innovation, will open its second funding round later this month, with AUD […]
More